Search

NA

Background and Design: Isotretinoin is a widely used retinoid for the treatment of many dermatological conditions notably in acne with many known side effects. This study aims to investigate the effects of isotretinoin on anti-Mullerian hormone (AMH), follicle stimulating hormone (FSH) and total antral follicle count (TAFC) as the indicators of ovarian reserve (OR) and also aims to investigate the frequency of menstrual irregularities (MI). Materials and Methods: Ninety-two reproductive women were included in this prospective controlled study. Study group is consisted of 32 healthy control, 29 low-dose (0.4-0.6 mg/kg/day mean: 0.56±0.06) and 31 high-dose isotretinoin received patients (0.7-1.1 mg/kg/day mean: 0.94±0.11). AMH, FSH and TAFC were evaluated before and at 6th month of treatment in the treatment group, while AMH and FSH levels were evaluated in the control group. Results: Mean AMH level of treatment group at the 6th month of treatment was significantly lower than the level prior to treatment and that of the control group (p

Omalizumab is a humanized monoclonal anti-immunoglobulin E which is originally developed for the treatment of allergic respiratory disorders, but has been approved for the treatment of antihistamine-resistant chronic spontaneous urticaria in 2014. It has become a game changer in the treatment of all subtypes of chronic urticaria (CU) even though it has not been yet approved for inducible urticarias. It is a safe drug with minor adverse events reported in the clinical trials as well as real life studies. The main questions that remain to be answered regarding its use for CU are the duration of treatment, how to cease the treatment and safety of long-term use. Available information about these questions are tried to be provided in this review.

Background and design: symptomatic dermographism (SD) is the most common form of the inducible urticaria that impairs quality of life significantly and requires further treatment. Guidelines recommend a stepwise approach starting with second-generation (sg) H1 antihistamines (AHs), and it has been advised that the same algorithm that is available for chronic spontaneous urticaria might be implemented in chronic inducible urticarias. However, there is a lack of clinical trials assessing the efficacy of AHs and omalizumab in patients with SD. In this study, we aimed to evaluate treatment responses in SD patients by using patient-reported outcomes and physician's assessment tools. Materials and Methods: this prospective observational study included 58 patients with SD. Treatment responses were evaluated with urticaria control test (UCT), patient's global assessment of disease severity (PatGA-VAS), physician's global assessment of disease control (PhyGA-VAS), and dermatology quality of life index (DLQI) at 0, 4, 8, 12 and 24th weeks of the treatment. Results: fifty-eight patients (40 women and 18 men) with a mean age of 36.9 +/- 12.38 years (range: 17-72) were included in the study. The mean disease duration of the patients was 31.8 +/- 46.22 months. Fifteen patients (43.1%) responded to single-dose sg-AHs, while 25 (43.1%) responded to updosing or combination of sg-AHs. The response was confirmed by increased UCT scores, PhyGA-VAS (p, NA